320 related articles for article (PubMed ID: 15115397)
21. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
De Corte BL
J Med Chem; 2005 Mar; 48(6):1689-96. PubMed ID: 15771411
[No Abstract] [Full Text] [Related]
22. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
24. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
25. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
[TBL] [Abstract][Full Text] [Related]
27. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
[TBL] [Abstract][Full Text] [Related]
29. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
30. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
32. Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
Butini S; Gemma S; Brindisi M; Borrelli G; Fiorini I; Samuele A; Karytinos A; Facchini M; Lossani A; Zanoli S; Campiani G; Novellino E; Focher F; Maga G
Bioorg Med Chem Lett; 2011 Jul; 21(13):3935-8. PubMed ID: 21636271
[TBL] [Abstract][Full Text] [Related]
33. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
34. Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Wan ZY; Yao J; Tao Y; Mao TQ; Wang XL; Lu YP; Wang HF; Yin H; Wu Y; Chen FE; De Clercq E; Daelemans D; Pannecouque C
Eur J Med Chem; 2015 Jun; 97():1-9. PubMed ID: 25935383
[TBL] [Abstract][Full Text] [Related]
35. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
36. Etravirine: R165335, TMC 125, TMC-125, TMC125.
Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
[TBL] [Abstract][Full Text] [Related]
37. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
38. Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors.
Azeem SM; Muwonge AN; Thakkar N; Lam KW; Frey KM
J Mol Graph Model; 2018 Jan; 79():133-139. PubMed ID: 29156381
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
Mai A; Artico M; Rotili D; Tarantino D; Clotet-Codina I; Armand-Ugón M; Ragno R; Simeoni S; Sbardella G; Nawrozkij MB; Samuele A; Maga G; Esté JA
J Med Chem; 2007 Nov; 50(22):5412-24. PubMed ID: 17910429
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
